Tags

Type your tag names separated by a space and hit enter

Current treatment and future prospects of dopa-induced dyskinesias.
Drugs Today (Barc). 2015 May; 51(5):315-29.DT

Abstract

Levodopa-induced dyskinesias (LID) are one of the main issues in the management of Parkinson's disease (PD); once these dyskinesias are established treatment becomes difficult, so preventive strategies should be first evaluated. Although levodopa (LD) treatment has recently been related as risk factor for LID, the main strategy to delay LID is to start PD treatment with dopamine agonists, adding LD at low doses. After LID onset, approaches include reducing single LD doses, reducing or discontinuing monoamine oxidase type B/catechol O-methyltransferase (MAO-B/COMT) inhibitors and extended-release (ER) LD. Amantadine represents the best antidyskinetic tool, and ER amantadine is the most promising upcoming antidyskinetic drug. New LD formulations such as IPX-066 (able to provide continuous dopaminergic stimulation) also represent promising new approaches. The involvement of a nondopaminergic system in the pathogenesis of LID suggests that the modulation of glutamate, serotonin and adenosine could have potential as new upcoming drug targets, but the role of such drugs will still need to be confirmed in randomized controlled trials.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. r.ceravolo@med.unipi.it.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26097904

Citation

Mazzucchi, S, et al. "Current Treatment and Future Prospects of Dopa-induced Dyskinesias." Drugs of Today (Barcelona, Spain : 1998), vol. 51, no. 5, 2015, pp. 315-29.
Mazzucchi S, Frosini D, Bonuccelli U, et al. Current treatment and future prospects of dopa-induced dyskinesias. Drugs Today (Barc). 2015;51(5):315-29.
Mazzucchi, S., Frosini, D., Bonuccelli, U., & Ceravolo, R. (2015). Current treatment and future prospects of dopa-induced dyskinesias. Drugs of Today (Barcelona, Spain : 1998), 51(5), 315-29. https://doi.org/10.1358/dot.2015.51.5.2313726
Mazzucchi S, et al. Current Treatment and Future Prospects of Dopa-induced Dyskinesias. Drugs Today (Barc). 2015;51(5):315-29. PubMed PMID: 26097904.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current treatment and future prospects of dopa-induced dyskinesias. AU - Mazzucchi,S, AU - Frosini,D, AU - Bonuccelli,U, AU - Ceravolo,R, PY - 2015/6/23/entrez PY - 2015/6/23/pubmed PY - 2015/10/17/medline KW - Dopaminergic modulation KW - IPX-066 KW - Levodopa-induced dyskinesias KW - Parkinson's disease SP - 315 EP - 29 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today (Barc) VL - 51 IS - 5 N2 - Levodopa-induced dyskinesias (LID) are one of the main issues in the management of Parkinson's disease (PD); once these dyskinesias are established treatment becomes difficult, so preventive strategies should be first evaluated. Although levodopa (LD) treatment has recently been related as risk factor for LID, the main strategy to delay LID is to start PD treatment with dopamine agonists, adding LD at low doses. After LID onset, approaches include reducing single LD doses, reducing or discontinuing monoamine oxidase type B/catechol O-methyltransferase (MAO-B/COMT) inhibitors and extended-release (ER) LD. Amantadine represents the best antidyskinetic tool, and ER amantadine is the most promising upcoming antidyskinetic drug. New LD formulations such as IPX-066 (able to provide continuous dopaminergic stimulation) also represent promising new approaches. The involvement of a nondopaminergic system in the pathogenesis of LID suggests that the modulation of glutamate, serotonin and adenosine could have potential as new upcoming drug targets, but the role of such drugs will still need to be confirmed in randomized controlled trials. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/26097904/Current_treatment_and_future_prospects_of_dopa_induced_dyskinesias_ DB - PRIME DP - Unbound Medicine ER -